TUF alum C.B. Dollaway has been hit by a two-year suspension handed down by USADA after three violations of the UFC’s anti-doping policy.
C.B. Dolloway will be out of action for a while. On Monday, USADA (U.S. Anti-Doping Agency), who handle the UFC’s Anti-Doping Policy, announced that Dollaway had accepted a two-year sanction after after a trio of infractions that took place between late 2018 and early 2019.
The fighter, currently competing in the UFC’s middleweight division, “tested positive for anastrozole, growth hormone releasing peptide 2 (GHRP-2 or pralmorelin), a metabolite of GHRP-2, and GHRP-6 as the result of an out-of-competition urine sample he provided on December 19, 2018,” USADA revealed via press release.
Months later, he “tested positive for clomiphene in an out-of-competition urine sample collected on February 9, 2019.” And in a third strike, Dollaway “received an over-the-limit intravenous (IV) infusion on December 13, 2018.” Although IV use is sometimes permitted under USADA and the UFC’s Anti-Doping Policy, injections or IVs of more than 100ml per 12 hour period is not allowed.
Dollaway’s three infractions were treated as a single, first-time infraction, meaning his two-year suspension became effective December 13, 2018, the date of the earliest violation.
After entering the UFC via The Ultimate Fighter in 2008, Dollaway (17–9) has been a regular, fighting at both light heavyweight and middleweight. Overall, he’s 11-9 in the big show, most recently suffering a ref stoppage loss to Khalid Murtazaliev at UFC Moscow last September. Prior to that, he’d earned wins over Hector Lombard and Ed Herman.
Coincidentally, Murtazaliev was also hit with a doping violation this year, and was suspended two years for steroid use. The Dollaway fight was his first in the UFC.
